文摘
摘要目的:调查工具的便携式ultra-low-field(64吨)的MRI (ULF-MRI)和可视化能力确定患者常见的影像学表现进步多病灶的脑白质病(PML)相比,轨迹(高频,3 t)核磁共振。
背景:PML是一种使人衰弱的中枢神经系统感染由JC病毒引起的。最近开发的便携式ULF-MRI技术对PML医疗点的后续潜在的影响。之前没有数据的可行性和实用ULF-MRI在PML检测常见的影像学表现。
设计/方法:患者从美国国立卫生研究院的自然历史研究PML -NCT01730131)。5例接受HF-MRI (3 t飞利浦)大脑的对比之后,ULF-MRI(俯冲,超精细)在相同的坐着,因此利用钆single-administration;2在2周内ULF-MRI HF-MRI,在这些情况下没有钆执行。ULF-MRI执行一个病人的床边。t1加权成像序列包括T2-FLAIR,醉酒驾车。扫描被neuroradiologist评估和神经神经成像技术。分析包括检测PML白质病变,对比度增强和限制扩散是否可以可视化在这些病变。
结果:7例女性(3)不同基础疾病,包括女士、艾滋病毒、原发性免疫缺陷,参加这个飞行员。3有活跃的PML, 1 PML-IRIS, 3是长期的幸存者。多病灶的PML所有患者病变在HF-MRI可视化;幕上的病变只有5/7,2/7 infratentorial疾病。相应病变被确定在所有情况下在ULF-MRI除了点状的病变,这并非一贯可视化。一个主题(PML-IRIS)展出HF-MRI对比度增强,显然可视化post-contrast ULF-MRI。没有病人呈现明显的扩散限制HF-MRI或ULF-MRI。
结论:ULF-MRI是可行的,即使在床边扫描,,需要继续调查在医疗点的设置定义可能的作用。
披露:先生从没有披露。Okar博士没有披露。米娜博士没有披露。弗莱彻博士没有披露。Azodi博士没有披露。帝国已经收到博士研究的机构国家卫生研究院的支持。帝国已经收到博士研究的机构支持顶点药品。帝国已经收到博士研究的机构阿德尔森医疗研究基金会的支持。帝国已经收到博士研究的机构支持髓修复的基础。Reich博士的机构已经接到Sanofi-Genzyme研究支持。 The institution of Dr. Reich has received research support from Abata Therapeutics. Dr. Reich has a non-compensated relationship as a Advisor with Sanofi-Genzyme that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Third Rock Ventures that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Board of Directors with ACTRIMS that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Scientific Advisory Board with Race to Erase MS Foundation that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Abata Therapeutics that is relevant to AAN interests or activities. Dr. Cortese has received stock or an ownership interest from Keires, AG. Dr. Cortese has received stock or an ownership interest from Nouscom, AG. Dr. Cortese has received stock or an ownership interest from PDC Pharma.
